Yousif Capital Management LLC Lowers Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Yousif Capital Management LLC lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,986 shares of the specialty pharmaceutical company’s stock after selling 852 shares during the quarter. Yousif Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $1,599,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter worth about $9,335,000. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Jazz Pharmaceuticals by 4.6% in the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $135.44 on Thursday. The business’s fifty day moving average is $122.97 and its 200 day moving average is $116.89. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $136.55. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market capitalization of $8.19 billion, a PE ratio of 19.08, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 5,053 shares of company stock valued at $617,442 in the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.